Welcome to our dedicated page for Strata Skin Sciences SEC filings (Ticker: SSKN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The STRATA Skin Sciences, Inc. (NASDAQ: SSKN) SEC filings page on Stock Titan aggregates the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, providing a structured view of how this medical technology issuer reports its operations, governance, and capital activities. As a Nasdaq-listed manufacturer of in-office dermatologic devices such as the XTRAC® excimer laser, VTRAC® lamp systems, and TheraClearX® Acne Therapy System, STRATA uses its SEC filings to detail financial performance, risk factors, reimbursement developments, and strategic initiatives.
Core periodic reports like the Form 10-K annual report and Form 10-Q quarterly reports contain audited and interim financial statements, segment information for dermatology recurring procedures and equipment, and management’s discussion of trends in recurring billings, equipment revenue, and margins. These filings also discuss dependencies on reimbursement under CPT® codes 96920–96922 for excimer laser procedures and outline key risks related to payer policies, clinical adoption, and competition in dermatology devices.
Current reports on Form 8-K provide more immediate insight into material events. STRATA has filed 8-Ks to announce quarterly financial results, registered direct offerings, at-the-market equity distribution arrangements, Nasdaq listing compliance notices, and investor presentations. These filings give context on capital raising activities, stockholders’ equity levels, and the company’s responses to Nasdaq’s continued listing requirements.
The company’s proxy statement on Form DEF 14A offers additional detail on corporate governance, director elections, equity incentive plans, and the selection of the independent registered public accounting firm. For investors tracking executive compensation structures, board oversight, and shareholder voting matters, the proxy materials are a primary reference.
On Stock Titan, users can access these STRATA filings alongside AI-powered summaries that highlight key points from lengthy documents, such as revenue composition, non-GAAP measures like adjusted EBITDA, and updates on reimbursement or litigation. The platform also surfaces real-time 8-Ks and other new submissions from EDGAR, helping users follow developments such as financing transactions, regulatory notices, and strategic disclosures without reading every page manually.
For those interested in trading dynamics and governance, Form 4 insider transaction reports and related ownership disclosures, when available, can be reviewed to see how STRATA’s officers, directors, or significant shareholders are transacting in SSKN shares. Together, these filings provide a detailed regulatory record of STRATA Skin Sciences’ financial condition, strategic direction, and compliance as a public dermatology device company.
Accelmed Partners and affiliated reporting persons disclose beneficial ownership of 1,441,835 shares of Strata Skin Sciences common stock, representing 27.4% of the outstanding shares. This Amendment No. 2 to Schedule 13D reports that the percentage calculation is based on 5,268,708 shares outstanding following a September 4, 2025 registered direct offering by the issuer that issued 1,097,547 new shares. The filing amends prior Schedule 13D information solely to reflect the change in percent of class; no transactions in the issuer's shares by the reporting persons occurred in the past 60 days. The reporting persons and signatory for this filing is Uri Geiger in his capacity as Managing Partner.
Strata Skin Sciences, Inc. reported that it has closed a previously announced registered direct offering of its common stock. The company issued and sold 1,097,547 shares of common stock at a purchase price of $2.204 per share, with Ladenburg Thalmann & Co. Inc. serving as the exclusive placement agent. The transaction details were disclosed in a press release dated September 4, 2025, which is furnished as an exhibit and not deemed filed for liability purposes under the securities laws.
Lincoln Alternative Strategies LLC reported beneficial ownership of 365,849 shares of Strata Skin Sciences, Inc. common stock, representing 6.94% of the outstanding shares based on 5,268,708 shares outstanding as of September 3, 2025. The filing is a Schedule 13G indicating passive ownership under the Exchange Act rules and expressly certifies the shares were not acquired to change or influence control of the issuer. The reporting entity is organized in Delaware and lists its principal business address in Miami Beach, FL. The filing was signed by Stephen Temes as Managing Member on September 4, 2025.
Strata Skin Sciences (SSKN) is offering securities under a prospectus supplement that contemplates sales of common stock at $2.204 per share and a variety of other instruments including preferred stock, debt securities, warrants, rights and units. The company estimates net proceeds of approximately $2.15 million after placement agent fees and offering expenses and intends to use proceeds for working capital and general corporate purposes. The supplement references risk factors and forward-looking statements and incorporates prior SEC reports including annual and quarterly filings and current reports filed through September 3, 2025. The prospectus describes detailed terms that may apply to each security type, including conversion, payment, redemption and tax considerations, and lists distribution methods such as underwriters, agents, direct sales and block trades.
Strata Skin Sciences, Inc. filed an 8-K reporting a material event linked to a securities transaction. The filing lists exhibits that include a Placement Agency Agreement, a Securities Purchase Agreement (form), legal opinion and consent from Stevens & Lee, P.C., and a Pricing Press Release dated
The filing itself provides the existence of agreements and a pricing announcement but does not disclose offering size, price, net proceeds, or other financial terms within the text provided. The company's disclosures establish that placement counsel and transactional agreements are in place and that a public pricing announcement was released on the date shown.
Strata Skin Sciences, Inc. disclosed that on August 19, 2025 Nasdaq notified the company it is not in compliance with the Nasdaq Capital Market minimum stockholders' equity requirement of $2,500,000. The company's Quarterly Report for the quarter ended June 30, 2025 reported stockholders' equity below that threshold and the company does not meet alternative Nasdaq standards related to market value of listed securities or net income from continuing operations.
The Notice does not immediately affect the listing and the common stock continues trading under the symbol SSKN. Nasdaq gave Strata 45 calendar days, until October 3, 2025, to submit a plan to regain compliance; if accepted, Nasdaq may grant up to 180 days from the Notice date to evidence compliance. The company is evaluating options and plans to timely submit a plan, but stated there is no assurance the plan will be accepted or that compliance will be achieved.
STRATA Skin Sciences, Inc. furnished an investor presentation to the market by posting it on its website and attaching it as Exhibit 99.1 to a current report. The presentation is dated August 2025 and is intended to provide additional information to investors about the company.
The material in this investor presentation, and the related exhibit, is being furnished under a current report rather than filed, which means it is not subject to certain liability provisions of the securities laws and is not automatically incorporated into other securities filings unless specifically referenced.
Strata Skin Sciences, Inc. filed a current report to let investors know it has issued a press release covering its results of operations for the second fiscal quarter ended June 30, 2025. The company furnished the full text of this press release as Exhibit 99.1 to the report, using Items 2.02 and 7.01 to share the information. The company states that this exhibit is being furnished, not filed, so it is not subject to certain Exchange Act liabilities or automatically incorporated into other securities filings unless specifically referenced.
FAQ
What is the current stock price of Strata Skin Sciences (SSKN)?
What is the market cap of Strata Skin Sciences (SSKN)?
